.Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AX16_Inclisiran.Inclisiran

Information

Inclisiran is a small interfering RNA (siRNA) drug that targets and degrades PCSK9 mRNA in the liver, leading to lower levels of LDL cholesterol. It is used in the treatment of hypercholesterolemia and is approved for use in adults with elevated LDL-C who are at high risk for cardiovascular events.

Pharmacokinetics

Pharmacokinetics in adult subjects with hypercholesterolemia or mixed dyslipidemia after a single subcutaneous dose.

References

1. Yamashita, S, et al., & Kajinami, K (2024). Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15. Journal of atherosclerosis and thrombosis 31(6) 876–903. DOI:10.5551/jat.64454 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38220186

2. Luo, Z, et al., & He, Y (2023). The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of clinical lipidology 17(3) 392–400. DOI:10.1016/j.jacl.2023.04.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37164838

3. Jeon, JY, et al., & Mitra, A (2022). Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview. Pharmaceutical research 39(8) 1749–1759. DOI:10.1007/s11095-022-03333-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35819583

Revisions

• 06/2025 initial generated model